3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
126
Lung Neoplasms
51
Triple Negative Breast Neoplasms
35
Breast Neoplasms
34
Small Cell Lung Carcinoma
30
Ovarian Neoplasms
27
Squamous Cell Carcinoma of Head and Neck
25
Neoplasm Metastasis
21
Fallopian Tube Neoplasms
20
Endometrial Neoplasms
19
Neoplasms
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Head and Neck Neoplasms
13
Colorectal Neoplasms
11
Carcinoma
11
Prostatic Neoplasms
9
Oropharyngeal Neoplasms
9
Esophageal Neoplasms
9
Urinary Bladder Neoplasms
8
Carcinoma, Transitional Cell
8
Pancreatic Neoplasms
7
Carcinoma, Squamous Cell
7
Lung Diseases
6
Laryngeal Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Adenocarcinoma of Lung
6
Uterine Cervical Neoplasms
5
Respiratory Tract Neoplasms
5
Mouth Neoplasms
5
Mesothelioma
5
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Urothelial Cancer
×
Carboplatin
×
90 days
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA